Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

Abstract:

:After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of anti-TNF therapy is complicated by loss of response. In order to maintain remission, adequate serum levels are required. Hence, therapeutic drug monitoring (TDM) is important in order to optimize serum drug levels, especially in patients with loss of response to these agents. Optimization of anti-TNF therapy by applying TDM enables clinicians to regain response to TNF blockers in a significant proportion of patients. It is important to use anti-TNF agents in their most optimal way, since these therapeutic agents are expensive and the medical options after failing anti-TNF therapy are limited. Here, we will discuss how to optimize treatment with anti-TNF agents in IBD patients in order to improve treatment efficacy, prevent anti-drug antibody formation, reduce side effects, discontinue unnecessary treatment and manage costs.

authors

Strik AS,Bots SJ,D'Haens G,Löwenberg M

doi

10.1586/17512433.2016.1133288

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

429-39

issue

3

eissn

1751-2433

issn

1751-2441

journal_volume

9

pub_type

杂志文章,评审
  • Antioxidants in the prevention of myocardial ischemia/reperfusion injury.

    abstract::In acute myocardial ischemia (AMI) the optimal treatment is rapid revascularization by angioplasty or pharmacological thrombolysis. While this is essential to resuscitate the ischemic myocardium, it results in further reperfusion injury and extension of the infarction. The main hypothesis for the mechanism of reperfus...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.41

    authors: Qin C,Yap S,Woodman OL

    更新日期:2009-11-01 00:00:00

  • Evolution of diagnostic approaches in betalactam hypersensitivity.

    abstract:INTRODUCTION:Betalactams are the most widely used drugs against infections and the primary cause of antibiotic hypersensitivity reactions. Reaction patterns for different betalactams have been changing in accordance with consumption trends, and vary among countries. As a consequence, in vivo and in vitro tests have had...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1313110

    authors: Fernandez TD,Mayorga C,Salas M,Barrionuevo E,Posadas T,Ariza A,Laguna JJ,Moreno E,Torres MJ,Doña I,Montañez MI

    更新日期:2017-06-01 00:00:00

  • Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.

    abstract:INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1333902

    authors: Watanabe Y,Tatsuno I

    更新日期:2017-08-01 00:00:00

  • Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.

    abstract::Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1100072

    authors: Ali KF,Shukla AP,Aronne LJ

    更新日期:2016-01-01 00:00:00

  • Sex and gender influences on pharmacological response: an overview.

    abstract::Research on the specific effects of sex and gender on pharmacokinetics and pharmacodynamics, as well as safety profile tolerability and drug efficacy, of medications remain meager because female animals and women have only recently been included in the pharmacological domain. To date, the influence of sex and gender o...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.922866

    authors: Franconi F,Campesi I

    更新日期:2014-07-01 00:00:00

  • Significance and applications of nanoparticles in siRNA delivery for cancer therapy.

    abstract::RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.33

    authors: Ali HM,Urbinati G,Raouane M,Massaad-Massade L

    更新日期:2012-07-01 00:00:00

  • Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance.

    abstract:INTRODUCTION:In the modern antimicrobial era, the rapid spread of resistance to antibiotics and introduction of new and mutating viruses is a global concern. Combating antimicrobial resistant microbes (AMR) requires coordinated international efforts that incorporate new conventional antibiotic development as well as de...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1371591

    authors: Enioutina EY,Teng L,Fateeva TV,Brown JCS,Job KM,Bortnikova VV,Krepkova LV,Gubarev MI,Sherwin CMT

    更新日期:2017-11-01 00:00:00

  • Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil.

    abstract:OBJECTIVES:To estimate the prevalence of polypharmacy (≥5 drugs) among adults and to analyze related factors. METHODS:Cross-sectional study with 1,159 interviewees distributed across 104 cities and 253 primary healthcare services delivered through the Brazilian Unified Health System. Polypharmacy-related factors were ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2020.1836958

    authors: Moreira T,Alvares-Teodoro J,Barbosa MM,Do Nascimento RCRM,Guerra Júnior AA,Acurcio FA

    更新日期:2020-12-01 00:00:00

  • Immunotherapy for gastric cancers: emerging role and future perspectives.

    abstract:INTRODUCTION:The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical d...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1313113

    authors: Bonotto M,Garattini SK,Basile D,Ongaro E,Fanotto V,Cattaneo M,Cortiula F,Iacono D,Cardellino GG,Pella N,Fasola G,Antonuzzo L,Silvestris N,Aprile G

    更新日期:2017-06-01 00:00:00

  • The genetics of vascular incidents associated with second-generation antipsychotic administration.

    abstract::Second-generation antipsychotics (SGA) have been associated with risk of stroke in elderly patients, but the molecular and genetic background under this association has been poorly investigated. The aim of the present study was to prioritize a list of genes with an SGA altered expression in order to characterize the g...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.865515

    authors: Cocchi E,Drago A,de Ronchi D,Serretti A

    更新日期:2014-01-01 00:00:00

  • Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review.

    abstract::Ziprasidone, a benzisothiazolyl piperazine derivative of tiospirone, is a second-generation antipsychotic with high-affinity antagonism for 5-hydroxytryptophan (5HT)(2A), 5HT(2C), 5HT(1D) and D(2) receptors, pre- and post-synaptic agonism for 5HT(1A) receptors, and inhibition of reuptake for serotonin and norepinephri...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.10.139

    authors: Sacchetti E,Galluzzo A,Valsecchi P

    更新日期:2011-03-01 00:00:00

  • Clinical applications of pharmacogenomics to adverse drug reactions.

    abstract::The problem of adverse drug reactions is a well-documented global public health problem. Recent withdrawals of several widely used prescription medications in the USA and other countries have raised concerns among patients, clinicians, scientists and policy makers. The increasing interest and concern regarding withdra...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.1.2.251

    authors: Issa AM

    更新日期:2008-03-01 00:00:00

  • Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.

    abstract:INTRODUCTION:The Pharmacokinetics/pharmacodynamics (PK/PD) relationships with cytotoxics are usually based on a steepening concentration-effect relationship; the greater the drug amount, the greater the effect. The Maximum Tolerated Dose paradigm, finding the balance between efficacy, while keeping toxicities at their ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1477586

    authors: Rodallec A,Fanciullino R,Lacarelle B,Ciccolini J

    更新日期:2018-06-01 00:00:00

  • Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality.

    abstract:INTRODUCTION:Osteoarthritis is the most common cause of arthritis and one of the main causes of chronic pain. Although opioids are frequently employed for chronic pain treatment, their usage for osteoarthritis pain remains controversial due to the associated adverse effects. Most guidelines reserve their use for refrac...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1381556

    authors: Ruiz Iban MA,Benavides J,Forero JP,Bittelman S,Martinez R,Mite MA,Diaz Heredia J,Ulloa S,Lizárraga Ferrand MM

    更新日期:2018-01-01 00:00:00

  • Pegloticase and the patient with treatment-failure gout.

    abstract::Gout is an inflammatory arthritis characterized by sudden, painful inflammation. Gout can affect any joint in an asymmetric distribution. Gouty attacks may be isolated or can be followed by years of recurrent flares. Over time, elevated serum urate levels and tophaceous deposits can lead to deformity and disability fr...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.12.48

    authors: Dave AJ,Kelly VM,Krishnan E

    更新日期:2012-09-01 00:00:00

  • Secukinumab (AIN-457) for the treatment of Psoriasis.

    abstract::Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1129894

    authors: Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

    更新日期:2016-01-01 00:00:00

  • Effects of red wine on established markers of arterial structure and function in human studies: current knowledge and future research directions.

    abstract::Evidence from observational studies suggests that mild-to-moderate consumption of red wine is associated with reduced cardiovascular morbidity and mortality. Various individual chemical components of red wine also show salutary effects on vascular homeostasis, that is, enhanced endothelial function and arterial disten...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2013.841077

    authors: Mangoni AA,Stockley CS,Woodman RJ

    更新日期:2013-11-01 00:00:00

  • A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).

    abstract::The aim of this article was to assess the efficacy and safety of apremilast in treatment of psoriatic arthritis (PsA) with meta-analysis method. We included four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast with place...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/17512433.2016.1159130

    authors: Qu X,Zhang S,Tao L,Song Y

    更新日期:2016-06-01 00:00:00

  • Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.

    abstract:INTRODUCTION:In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy and safety is not well characterized. Different efficacy and safety profiles in children of varying ages may be anticipated, due to developmental changes occurring across pediatric life. AREAS COVERED:Beside pharmacokine...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1198256

    authors: Brussee JM,Calvier EA,Krekels EH,Välitalo PA,Tibboel D,Allegaert K,Knibbe CA

    更新日期:2016-09-01 00:00:00

  • Combating inappropriate use of medicines.

    abstract::Globally, it is possible that less than half of all patients are treated in compliance with guidelines and more than half of all patients fail to take their medicines as prescribed or dispensed. Such inappropriate use is wasteful of resources and causes patient harm in terms of lack of satisfactory outcome, serious ad...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.14

    authors: Holloway KA

    更新日期:2011-05-01 00:00:00

  • Advanced stage pancreatic cancer: novel therapeutic options.

    abstract::Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, it continues to be a therapeutic challenge. Gemcitabine approved by FDA in 1997, offers modest improvement of tumor-related symptoms and marginal advantage of survival. Many chemotherapeutic agents have been compared against...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.910451

    authors: Saif MW

    更新日期:2014-07-01 00:00:00

  • Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.

    abstract::Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world. Hepatotoxicity is a rare but serious side effect resulting from its use, particularly in young patients. This adverse effect does not dis...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.871202

    authors: Felker D,Lynn A,Wang S,Johnson DE

    更新日期:2014-03-01 00:00:00

  • Immunopharmacology: utilizing antibodies as ion channel modulators.

    abstract::Development of the patch clamp technique by the Nobel Prize winners Bert Sakmann and Erwin Neher led to huge advances in ion channel research. Their work laid the foundations and revolutionized electrophysiological studies of cells and ion channels. These ion channels underlie many basic cellular physiological process...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.10.18

    authors: Dallas ML,Deuchars SA,Deuchars J

    更新日期:2010-05-01 00:00:00

  • Atezolizumab for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high ne...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1356717

    authors: Santini FC,Rudin CM

    更新日期:2017-09-01 00:00:00

  • VEGF-targeted therapy and beyond: pharmacotherapy and emerging treatments in agerelated macular degeneration.

    abstract::Treatment of age-related macular degeneration (AMD) has changed dramatically over the last decade. It has evolved from primarily destructive therapies (laser-based treatment strategies) to nondestructive therapies (intravitreal pharmacotherapies that target angiogenesis). Intermittent intravitreal ranibizumab, an inhi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.10.6

    authors: McGimpsey SJ,Chakravarthy U

    更新日期:2010-03-01 00:00:00

  • Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

    abstract::Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1665026

    authors: Ahmed SR,Petersen E,Patel R,Migden MR

    更新日期:2019-10-01 00:00:00

  • Pharmacological treatment of pediatric Gaucher disease.

    abstract:INTRODUCTION:Gaucher disease (GD) is an autosomal recessive disorder resulting from the deficiency of the lysosomal enzyme glucocerebrosidase (b-glucosidase), associated with varying degrees of visceral, bone and central nervous system pathology, leading to wide phenotypic diversity. Response to therapy and clinical ou...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1549486

    authors: Gupta P,Pastores G

    更新日期:2018-12-01 00:00:00

  • A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

    abstract::Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1552134

    authors: Esposito A,Viale G,Criscitiello C,Curigliano G

    更新日期:2019-01-01 00:00:00

  • Sugammadex: a novel selective relaxant binding agent.

    abstract::Sugammadex, a modified γ-cyclodextrin, is the first selective relaxant binding agent. Sugammadex forms very tight complexes in a 1:1 ratio with steroidal neuromuscular blocking agents (rocuronium > vecuronium > pancuronium). This guest-host complex, which exists in equilibrium, is stable because of its very high assoc...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2.1.37

    authors: Naguib M,Brull SJ

    更新日期:2009-01-01 00:00:00

  • Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.

    abstract::In the management of chronic obstructive pulmonary disease (COPD), there is an unmet medical need for effective bronchodilator treatments that not only have a fast onset of action, but also a long duration of action and are delivered using a simple, easy-to-use device. Long-acting muscarinic antagonists such as glycop...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2013.828419

    authors: Molimard M,D'Andrea P

    更新日期:2013-09-01 00:00:00